Concordance between thyroglobulin antibody assays

Taylor, Kevin; Parkington, Damon; Bradbury, Sonia; Simpson, Helen; Jefferies, Sarah; Halsall, David

doi:10.1258/acb.2011.010248

Cited by 24 publications

(10 citation statements)

References 5 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study also emphasizes that assays used to detect TgAbs are highly discordant . Using an experimental model induced by the administration of GVAX, we were able to show that in patients who did not have thyroid autoimmunity at baseline, TgAbs developed after GVAX and could be detected mainly by an assay that employs an intact form of human thyroglobulin.…”

Section: Discussionmentioning

confidence: 76%

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

et al. 2014

View full text Add to dashboard Cite

Cancer immunotherapy induces a variety of auto-inflammatory responses, including those against the thyroid gland, which can be exploited to predict clinical outcomes. Considering the paucity of information about thyroid autoimmunity in patients receiving cancer vaccines, we designed the present study to assess the development of thyroglobulin antibodies (TgAbs) in patients treated with GVAX and/or ipilimumab and correlated seroconversion with survival. Using both in house and commercial ELISA assays, we measured TgAbs in patients with pancreatic (No. = 53), prostate (No.= 35), or colon (No.= 8) cancer, before and after treatment with GVAX only (No= 34), GVAX plus ipilimumab (No = 42), or ipilimumab (No =20), and correlated their levels with patient’s survival, disease status, and T cell surface markers. Antibodies to thyroperoxidase, myeloperoxidase, proteinase 3, insulin and actin were also measured. TgAbs specifically developed after GVAX, independent of the underlying cancer (81% in prostate, 75% colon cancer, and 76% pancreatic cancer) and co-administration of ipilimumab (75% in GVAX only and 78% in GVAX plus ipilimumab). This TgAbs seroconversion could be detected mainly by the in house assay, suggesting that the thyroglobulin epitopes recognized by the antibodies induced by GVAX are different from the epitopes seen in the classic form of Hashimoto thyroiditis. Notably, TgAbs seroconversion was associated with significantly prolonged survival (p=0.01 for pancreas and p= 0.005 for prostate cancer). In conclusion, GVAX immunotherapy induces the appearance of TgAbs that recognize a unique antigenic repertoire and associate with prolonged survival.

show abstract

Section: Discussionmentioning

confidence: 76%

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Spencer et al [19] suggest that high levels may predict the likelihood of recurrence in patients without Hashimoto thyroiditis. Despite additional factors, as insensitivity and interference from high endogenous Tg concentrations [19][20][21], the antiTgAb seem to be a potential tumour marker and predictive response factor, since it may reflect viable malignant thyroid tissue.…”

Section: Discussionmentioning

confidence: 99%

Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer

et al. 2018

View full text Add to dashboard Cite

Aim: Based on the response criteria of the 2015 American Thyroid Associations guidelines, our objectives were to determine the response rate when using a low dose of 131-I GBq in patients with low-risk differentiated thyroid cancer (LRDTC) and the influence of clinical and analytical variables on the prediction of complete response. Methods: We performed a multicentre and longitudinal study, including patients who were operated for LRDTC and who underwent radioiodine remnant ablation with a low-dose of 131-I. All patients were assessed at 6–12 months, and their status was classified as complete (excellent response) or incomplete response (structural incomplete, biochemical incomplete or indeterminate response). Various factors including age, gender, histology, tumour focality and size, stage, time from surgery to treatment, type of thyroid-stimulating hormone (TSH) stimulation, preablation serum thyroglobulin (pTg), antiTg antibodies (pAntiTgAb) and TSH (pTSH) levels were also analysed in order to predict the complete response rate. Results: Of 108 patients, 79.6% achieved complete response and the remaining showed incomplete response (2.9, 5.5 and 12% due to biochemical incomplete, structural incomplete and indeterminate response respectively). Six patients received a new dose of 131-I. Tumour size and pAntiTgAb were the only factors related to therapeutic response (p = 0.03 and p < 0.01, respectively). However, pAntiTgAb was the only independent factor related to complete response. Patients with complete response showed lower pTg than those with incomplete response (5.1 ± 12.9 vs. 11.2 ± 25 ng/mL) although without statistical significance (p = 0.14). There was no significant difference in the response rate depending on the thyrotropin stimulation methods. Conclusions: A low dose of 131-I was sufficient for reaching a complete response at 6–12 months of follow-up in the majority of patients with LRDTC. Tumour size and pAntiTgAb variables were related to therapeutic response.

show abstract

“…A protocol specifying the collection conditions (collection fluid and volume) should be agreed between clinician and laboratory before samples are collected ( 4, D). Non‐serum samples tested with serum tumour marker assays should always be subjected to additional quality‐assessment measures, such as serial dilutions (to ensure linear dilution and confirm that the sample is not affected by the hook affect) and spike recovery experiments ( 4,D). …”

Section: Appendixmentioning

confidence: 99%